Abstract:Most breast cancers express estrogen receptor (ER) α, and the antiestrogen drug tamoxifen has been widely used for their treatment. Unfortunately, up to half of all ERα-positive tumors have intrinsic or acquired endocrine therapy resistance. Our recent studies revealed that the ER coactivator Mediator Subunit 1 (MED1) plays a critical role in tamoxifen resistance through cross-talk with HER2. Herein, we assembled a three-way junction (3-WJ) pRNA-HER2apt-siMED1 nanoparticle to target HER2-overexpressing human breast cancer via an HER2 RNA aptamer to silence MED1 expression. We found that these ultracompact RNA nanoparticles are very stable under RNase A, serum, and 8 M urea conditions. These nanoparticles specifically bound to HER2-overexpressing breast cancer cells, efficiently depleted MED1 expression, and significantly decreased ERα-mediated gene transcription, whereas point mutations of the HER2 RNA aptamer on these nanoparticles abolished such functions. The RNA nanoparticles not only reduced the growth, metastasis, and mammosphere formation of the HER2-overexpressing breast cancer cells but also sensitized them to tamoxifen treatment. These biosafe nanoparticles efficiently targeted and penetrated into HER2-overexpressing tumors after systemic administration in orthotopic xenograft mouse models. In addition to their ability to greatly inhibit tumor growth and metastasis, these nanoparticles also led to a dramatic reduction in the stem cell content of breast tumors when combined with tamoxifen treatment in vivo. Overall, we have generated multifunctional RNA nanoparticles that specifically targeted HER2-overexpressing human breast cancer, silenced MED1, and overcame tamoxifen resistance.

Pcdna3.1(−)-Mediated Ribozyme Targeting of HER-2 Suppresses Breast Cancer Tumor Growth

An Artificial Mirna Against Hpse Suppresses Melanoma Invasion Properties, Correlating With A Down-Regulation Of Chemokines And Mapk Phosphorylation

Mir-433 Inhibits Breast Cancer Cell Growth Via the MAPK Signaling Pathway by Targeting Rap1a

Attenuation of Telomerase Activity by Hammerhead Ribozyme Targeting Human Telomerase Rna Induces Growth Retardation and Apoptosis in Human Breast Tumor Cells.

Reversal of drug resistance in breast carcinoma cells by anti-mdr1 ribozyme regulated by the tumor-specific MUC-1 promoter.

Reversion of the malignant phenotype of gastric cancer cell SGC7901 by c-erbB-2 –specific hammerhead ribozyme

Reversal of multidrug resistance of tumor cells by anti-mdr1 ribozyme]

[Vector-Mediated HER-2 RNA Interference Against HER-2-positive Breast Cancer].

Inhibition of Telomerase in Tumor Cells by Ribozyme Targeting Telomerase RNA Component.

Reversal MDR in Breast Carcinoma Cells by Transfection of Ribozyme Designed According the Secondary Structure of Mdr1 Mrna.

In vitro cleavage of mdrl mrna fragment by synthetic ribozyme (rz) and transcribed ribozyme from tna-trimming plasmid

The Hammerhead Ribozyme Mediated Repression of VEGF for Cancer Gene Therapy

Silencing of HER2 Receptor and Growth Inhibition of SKBR3 Breast Cancer Cells by Lentiviral- Mediated RNAi

Stable RNA interference of ErbB-2 gene synergistic with epirubicin suppresses breast cancer growth in vitro and in vivo.

Overcoming Tamoxifen Resistance of Human Breast Cancer by Targeted Gene Silencing Using Multifunctional Prna Nanoparticles.

Intensive Inhibition of Htert Expression by a Ribozyme Induces Rapid Apoptosis of Cancer Cells Through a Telomere Length Independent Pathway

Study on Telomerase Inhibition by Ribozyme Targeted to Telomerase RNA Component

Experimental Cancer Gene Therapy by Multiple Anti-Survivin Hammerhead Ribozymes

Screening of deoxyribozyme with high reversal efficiency against multidrug resistance in breast carcinoma cells.

Inhibition of Telomerase Activity by Ribozyme Targeted to Human Telomerase Transcriptase

Ribozyme-Mediated Cleavage of the Estrogen Receptor Messenger Rna and Inhibition of Receptor Function in Target Cells